BCAX Stock — Bicara Therapeutics Inc.

Bicara Therapeutics Inc. (BCAX)

Updated October 16, 2026.

BCAX is a Stock. Total return is -6.8% over the past 2.1 years, 46.9 points behind SPY at 40.1%.

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors, with its lead program being ficerafusp alfa, a bifunctional antibody combining an epidermal growth factor receptor-directed monoclonal antibody with human transforming growth factor beta. The company does not currently have an established distribution schedule. Bicara appeals to investors seeking exposure to early-stage biotech development, where capital appreciation potential exists alongside the typical risks of clinical-stage drug development.

BCAX performance versus SPY

Price and return data through 2026-10-16.

Total return is -6.8% over the past 2.1 years, 46.9 points behind SPY at 40.1%. Over the past year its total return — price change plus distributions reinvested — is -10.2%. Its deepest 1-year drawdown was 46.0%.

BCAX key facts

Asset type

Stock

Asset class

Equity

Inception date

09/12/2024

Distribution frequency

None

Last close

$16.78 (as of 2026-10-16)

Market cap

$1,110,381,833

Average volume

819996.0

Beta

-0.693

Payout ratio

0.0%

EPS

$-3.08

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BCAX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 46.0%.

Who may consider BCAX — and who may not

It is a weaker fit for investors who need monthly cash flow (BCAX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BCAX

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions